These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 38808848)
1. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis. Ciapponi A; Bardach A; Colaci C; Rodríguez Cairoli F; Argento F; Korbenfeld E; García Martí S Rev Peru Med Exp Salud Publica; 2024 May; 41(1):7-18. PubMed ID: 38808848 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer. Iwata H; Xu B; Kim SB; Chung WP; Park YH; Kim MH; Tseng LM; Chung CF; Huang CS; Kim JH; Chiu JWY; Yamashita T; Li W; Egorov A; Nishijima S; Nakatani S; Nishiyama Y; Sugihara M; Cortés J; Im SA Cancer Sci; 2024 Sep; 115(9):3079-3088. PubMed ID: 38979893 [TBL] [Abstract][Full Text] [Related]
3. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Paracha N; Reyes A; Diéras V; Krop I; Pivot X; Urruticoechea A Breast Cancer Res Treat; 2020 Apr; 180(3):597-609. PubMed ID: 32100144 [TBL] [Abstract][Full Text] [Related]
4. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Cortés J; Hurvitz SA; Im SA; Iwata H; Curigliano G; Kim SB; Chiu JWY; Pedrini JL; Li W; Yonemori K; Bianchini G; Loi S; Borges GS; Wang X; Bachelot T; Nakatani S; Ashfaque S; Liang Z; Egorov A; Hamilton E Nat Med; 2024 Aug; 30(8):2208-2215. PubMed ID: 38825627 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis. Yeh Y; Chen C; Ko Y J Cancer Res Ther; 2022; 18(4):1061-1072. PubMed ID: 36149162 [TBL] [Abstract][Full Text] [Related]
7. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Kınıkoğlu O; Odabas H; Altıntaş YE; Yıldız A; Çakan B; Akdağ G; Yıldırım S; Bal H; Kaya T; Tünbekici S; Işık D; Başoğlu T; Yıldırım ME; Turan N Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929568 [No Abstract] [Full Text] [Related]
8. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654 [TBL] [Abstract][Full Text] [Related]
9. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment. Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076 [TBL] [Abstract][Full Text] [Related]
10. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717 [TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020 [TBL] [Abstract][Full Text] [Related]
12. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616 [TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting. Hu S; Wu Y; Luan J; Wang S; Fan G J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082 [TBL] [Abstract][Full Text] [Related]
17. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671 [TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Squires H; Stevenson M; Simpson E; Harvey R; Stevens J Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972 [TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091 [TBL] [Abstract][Full Text] [Related]
20. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]